🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Meghan Shea

Beth Israel Deaconess Medical Center

ORCID: 0000-0001-5262-1245

Also affiliated with Harvard University, Hadassah Medical Center, Beth Israel Deaconess Hospital

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.757Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079

Top 27%

0.757DataRank

Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Papers

Driven by 7 papers — median percentile 73. Top paper: “A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice”.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079

Top 27%

0.757DataRank

Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.05.028

N/A

0DataRank · unranked

22 citations

Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri +10 more

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.37120

N/A

0DataRank · unranked

165 citations

Ritu R. Gill, Page Widick, Poorva Bindal, Danielle C. McDonald, Meghan Shea +3 more

Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts

Gynecologic Oncology(2020)10.1016/j.ygyno.2019.10.031

N/A

0DataRank · unranked

55 citations

Diana Miao, Douglas I. Lin, Cynthia Hayne, Brooke E. Howitt, John L. Dalrymple +5 more

Heterogeneity in the Returns to Credits for Public Two-Year College Entrants

Research in Higher Education(2021)10.1007/s11162-021-09654-8

N/A

0DataRank · unranked

3 citations

Meghan Shea, Lauren Schudde

Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinic

The FASEB Journal(2023)10.1096/fj.202201952r

N/A

0DataRank · unranked

11 citations

Melanie K. Szahaj, Roelof H. Bekendam, Sienna E. Wurl, Megan M. Pantos, Christina A. Verbetsky +8 more

Evaluating meaningful levels of financial toxicity in gynecologic cancers

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2021-002475

N/A

0DataRank · unranked

112 citations

Annika Gompers, Michele R. Hacker, Sara Bouberhan, Meghan Shea, Sarah S. Summerlin +5 more